|
NV-18
|
DB05886 |
[NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma (cancer of the gall bladder).] |
|
8-Bromoadenosine-5'-Diphosphate
|
DB04554 |
|
|
Diphthamide
|
DB03223 |
|
|
2-Formyl-Protoporphryn Ix
|
DB03224 |
|
|
Cytidine-5'-Diphosphate
|
DB04555 |
[Cytidine 5'-(trihydrogen diphosphate). A cytosine nucleotide containing two phosphate groups esterified to the sugar moiety. Synonyms: CRPP; cytidine pyrophosphate. [PubChem]] |
|
Seletracetam
|
DB05885 |
[Seletracetam is a pyrrolidone derivative and with a structural similarity to newer generation antiepileptic drug levetiracetam. It binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppression in models of acquired and genetic epilepsy with high CNS tolerability. It is predicted to have low drug-drug interactions and inhibition or induction of any major human metabolizing enzymes. Seletracetam was in Phase II clinical trials under the supervision of the U.S. Food and Drug Administration (FDA) investigated as treatment of epilepsy and partial epilepsy however its development had been put on hold in July 2007. As of 2010, its production was further halted due to the investigation of a newer antiepileptic agent, brivaracetam.] |
|
HCV-086
|
DB05884 |
[HCV-086 is a small molecule antiviral designed to block an enzyme required for the replication of the hepatitis C virus.] |
|
Niflumic acid
|
DB04552 |
[Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.] |
|
AL7099A
|
DB03221 |
|
|
dATP
|
DB03222 |
|
|
2-Oxobutanoic Acid
|
DB04553 |
|
|
ABX-PTH
|
DB05883 |
[ABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform. This drug targets and neutralizes the action of parathyroid hormone (PTH) for the treatment of a secondary hyperparathyroidism.] |
|
4-Acetamido-2,4-Didexoy-D-Glycero-Beta-D-Galacto-Octopyranosylphosphonic Acid
|
DB04561 |
|
|
Adenosine-5'-Propylphosphate
|
DB03230 |
|
|
RI 624
|
DB05892 |
[RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.] |
|
3-(5-Amino-7-oxo-3,7-dihydro-2H-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl)-N-(2-{[2-(hydroxymethyl)phenyl]sulfanyl}benzyl)benzamide
|
DB03231 |
|
|
Tricarballylic Acid
|
DB04562 |
|
|
4,7-Dioxosebacic Acid
|
DB04560 |
|
|
Veglin
|
DB05890 |
[VEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma. Veglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in the ongoing struggle to combat malignant mesothelioma.] |
|
Tomivosertib
|
DB15219 |
[Tomivosertib is under investigation in clinical trial NCT03318562 (A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC).] |
